Market Place
Sourcing Support
Korro to Present at the Jefferies London Healthcare Conference
14 Nov 2024 //
GLOBENEWSWIRE
Korro Files for KRRO-110 First-In-Human Study, Forms Advisory Board
04 Nov 2024 //
GLOBENEWSWIRE
Korro Presents At Oligonucleotide Therapeutics Society Meeting
30 Sep 2024 //
GLOBENEWSWIRE
Novo Nordisk`s latest RNA deal involves $530M biobucks to sing in Korro`s opera
17 Sep 2024 //
FIERCE BIOTECH
Korro to Participate in Upcoming Investor Conferences
10 Sep 2024 //
GLOBENEWSWIRE
Korro Announces Board Changes: Knobil Joins, Lucchino Resigns
28 Aug 2024 //
GLOBENEWSWIRE
Korro to Participate in Upcoming September Investor and Scientific Conferences
27 Aug 2024 //
GLOBENEWSWIRE
Korro Reports Q2 2024 Results And Provides Business Updates
13 Aug 2024 //
GLOBENEWSWIRE
Korro Joins the Russell 2000®, Russell 3000®, and Russell Microcap® Indexes
01 Jul 2024 //
GLOBENEWSWIRE
Korro to Participate in Upcoming June Investor and Scientific Conferences
30 May 2024 //
GLOBENEWSWIRE
Korro Presents Additional KRRO-110 Preclinical Data At ATS 2024
20 May 2024 //
GLOBENEWSWIRE
Korro Reports Q1 2024 Results, Appoints Kemi Olugemo As CMO
14 May 2024 //
GLOBENEWSWIRE
Korro Announces $70 Million Private Placement
18 Apr 2024 //
GLOBENEWSWIRE
Korro to Participate in Upcoming Investor Conferences
01 Apr 2024 //
GLOBENEWSWIRE
Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress
26 Mar 2024 //
GLOBENEWSWIRE
Korro to Present at the TD Cowen 44th Annual Health Care Conference
27 Feb 2024 //
GLOBENEWSWIRE
Korro Bio Highlights Data for its Lead Program in AATD
18 Jan 2024 //
GLOBENEWSWIRE
Korro to Present at the 42nd Annual J.P. Morgan Healthcare Conference
04 Jan 2024 //
GLOBENEWSWIRE
Korro Announces Selection of its First Development Candidate for AATD
07 Dec 2023 //
GLOBENEWSWIRE
Korro Bio Appoints Dr. Rachel Meyers to Board of Directors
28 Nov 2023 //
GLOBENEWSWIRE
Korro Bio and Frequency Therapeutics Announce Closing of Merger
03 Nov 2023 //
GLOBENEWSWIRE
Korro Bio Announces Appointment of Tim Pearson to Board of Directors
25 Oct 2023 //
GLOBENEWSWIRE
Korro Bio and Frequency Therapeutics Announce Merger Agreement
14 Jul 2023 //
BUSINESSWIRE
Korro Strengthens Leadership Team Appointment of Shelby Walker General Counsel
10 May 2023 //
BUSINESSWIRE
Korro Bio and Genevant Sciences Enter into Collaboration Agreement
07 Mar 2023 //
BUSINESSWIRE
Korro Bio, Genevant to Develop RNA Editing Therapeutic
07 Mar 2023 //
CONTRACT PHARMA
Korro Bio Appoints Dr. Steve Colletti as Chief Scientific Officer
28 Feb 2023 //
BUSINESSWIRE
Lilly pays $75M to widen RNA editing deal with ProQR
23 Dec 2022 //
BIOPHARMADIVE
Korro Bio Expands Leadership Team with Key Appointments
08 Nov 2022 //
BUSINESSWIRE
Korro Bio to Participate in 2022 Jefferies Healthcare Conference
06 Jun 2022 //
BUSINESSWIRE
Korro Bio sings to the tune of $116M for its OPERA RNA editing program
05 Jan 2022 //
FIERCEBIOTECH
Software for the DNA hardware: Chroma snags $125M for epigenome
18 Nov 2021 //
FIERCEBIOTECH
Bermingham`s Korro Bio lands ex-Corvidia executive as CEO
11 Nov 2020 //
FIERCE BIOTECH
